Gsα mutations in hyperfunctioning thyroid adenomas

Archives of Medical Research

Volumn 30, Issue 6, 1999, Pages 514-521

  Murakami, Masami ^a   Kamiya, Yuji ^a   Yanagita, Yasuhiro ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Gunma Cancer Center   (Japan)

Author keywords

Adenylyl cyclase; Cyclic AMP; G protein; Thyrotropin receptor

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; THYROTROPIN; THYROTROPIN RECEPTOR;

AMINO ACID SEQUENCE; CARCINOGENESIS; GENE MUTATION; HUMAN; MITOGENESIS; PATHOPHYSIOLOGY; PROTEIN STRUCTURE; RECEPTOR GENE; REVIEW; SIGNAL TRANSDUCTION; THYROID ADENOMA; THYROID TUMOR;

ADENOMA; ANIMALS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MUTATION; ONCOGENE PROTEINS; THYROID NEOPLASMS;

EID: 0033383790     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(99)00078-8     Document Type: Review

References (53)

1. Bourne H.R., Sanders D.A., McCormick F. The GTPase superfamily. conserved structure and molecular mechanisms Nature. 349:1991;117.
2. Neer E.J. Heterotrimeric G proteins. organizers of transmembrane signals Cell. 80:1995;249.
3. Gutkind J.S. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein cascade. J Biol Chem. 273:1998;1839.
4. Vassart G., Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev. 13:1992;596.
5. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., Duh Q.-Y., Clark O.H., Kawasaki E., Bourne H.R., McCormick F. Two G protein oncogenes in human endocrine tumors. Science. 249:1990;655.
6. O'Sullivan C., Barton C.M., Staddon S.L., Brown C.L., Lemoine N.R. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog. 4:1991;345.
7. Russo D., Arturi F., Wicker R., Chazenbalk G.D., Schlumberger M., Du Villard J.A.D., Caillou B., Monier R., Parmentier C., Suarez H.G. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab. 80:1995;1347.
8. Du Villard J.A., Schlumberger M., Wicker R., Caillou B., Rochefort P., Feunteun J., Monier R., Parmentier C., Suarez H.G. Role of ras and gsp oncogenes in human epithelial thyroid tumorigenesis. J Endocrinol Invest. 18:1995;124.
9. Hamacher C., Studer H., Zbaeren J., Schatz H., Derwahl M. Expression of functional stimulatory guanine nucleotide binding protein in nonfunctioning thyroid adenomas is not correlated to adenyl cyclase activity and growth of these tumors. J Clin Endocrinol Metab. 80:1995;1724.
10. Tanaka K., Nagayama Y., Takeshita A., Namba H., Yamashita S., Niwa M., Nagataki S. Low incidence of the stimulatory G protein α-subunit mutations in autonomously functioning thyroid adenomas in Japan. Thyroid. 6:1996;195.
11. Parma J., Duprez L., Van Sande J., Hermans J., Rocmans P., Van Vilet G., Costagliola S., Rodien P., Dumont J.E., Vassart G. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gsα genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab. 82:1997;2695.
12. Kamiya Y., Murakami M., Yanagita Y., Koitabashi H., Nagamachi Y., Hosoi Y., Ogiwara T., Mizuma H., Iriuchijima T., Mori M. Primary culture of cells from hyperfunctioning thyroid adenoma with an activating mutation of Gα Mol Cell Endocrinol. 138:1998;137.
13. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J.E., Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 365:1993;649.
14. Paschke R., Tonacchera M., Van Sande J., Parma J., Vassart G. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab. 79:1994;1785.
15. Porcellini A., Ciullo I., Laviola L., Amabile G., Fenzi G., Avvedimento V.E. Novel mutations of thyrotropin receptor in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab. 79:1994;657.
16. 2+ cascades Mol Endocrinol. 9:1995;725.
17. Russo D., Arturi F., Suarez H.G., Schlumberger M., Du Villard J.-A., Crocetti U., Filetti S. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab. 81:1996;1548.
18. Watson N., Linder M.E., Druey K.M., Kehrl J.H., Blumer K.J. RGS family members. GTPase activating proteins for heterotrimeric G-protein α-subunit Nature. 383:1996;172.
19. Hunt T.W., Fields T.A., Casey P.J., Peralta E.G. RGS10 is a selective activator of Gαi GTPase activity. Nature. 383:1996;175.
20. Wall M.A., Coleman D.E., Lee E., Iñiguez-Lluhi J.A., Posner B.A., Gilman A.G., Sprang S.R. The structure of the G protein heterotrimer Giα1β1γ2. Cell. 83:1995;1047.
21. Laugwitz K.L., Allgeier A., Offermanns S., Spicher K., Van Sande J., Dumont J.E., Schultz G. The human thyrotropin receptor. a heptahelical receptor capable of stimulating members of all four G protein families Proc Natl Acad Sci USA. 93:1996;116.
22. Dumont J.E., Jauniaux J.C., Roger P.P. The cAMP-mediated stimulation of cell proliferation. Trends Biochem Sci. 14:1989;67.
23. Vallar L., Spada A., Giannattasio G. Altered Gs and adenylate cyclase activity in human GH secreting pituitary adenomas. Nature. 330:1987;566.
24. Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., Vallar L. GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 340:1989;692.
25. Führer D., Holzapfel H.-P., Wonerow P., Scherbaum W.A., Paschke R. Somatic mutations in the thyrotropin receptor gene and not in the Gsα protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab. 82:1997;3885.
26. Pinducciu C., Borgonovo G., Arezzo A., Torre G.C., Giordano G., Cordera R. Toxic thyroid adenoma. absence of DNA mutations of the TSH receptor and Gsα Eur J Endocrinol. 138:1998;37.
27. Suarez H.Z., Du Villard J.A., Caillou B., Schlumberger M., Parmentier C., Monier R. gsp Mutations in human thyroid tumours. Oncogene. 6:1991;677.
28. Goretzki P.E., Lyons J., Stacy-Phipps S., Rosenau W., Demeure M., Clark O.H., McCormick F., Röher H.-D., Bourne H.R. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg. 16:1992;576.
29. Matsuo K., Friedman E., Gejman P.V., Fagin J.A. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumours. structural studies of the TSH-R and the α-subunit of Gs in human thyroid neoplasms J Clin Endocrinol Metab. 76:1993;1446.
30. Yoshimoto K., Iwahana H., Fukuda A., Sano T., Itakura M. Rare mutations of the Gs alpha subunit gene in human endocrine tumours. Mutation detection by polymerase chain reaction-primer introduced restriction analysis. Cancer. 72:1993;1386.
31. Gorelov V.N., Röher H.-D., Goretzki P.E. A method to increase the sensitivity of mutation specific oligonucleotide hybridization using asymmetric polymerase-chain reaction (PCR). Biochem Biophys Res Commun. 200:1994;365.
32. Challeton C., Bounacer A., Du Villard J.A., Caillou B., De Vathaire F., Monier R., Schlumberger M., Suarez H.G. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumours. Oncogene. 11:1995;601.
33. Esapa C., Foster S., Johnson S., Jameson J.L., Kendall-Taylor P., Harris P.E. G protein and thyrotropin receptor mutations in thyroid neoplasia. J Clin Endocrinol Metab. 82:1997;493.
34. Takeshita A., Nagayama Y., Yokoyama N., Ishikawa N., Ito K., Yamashita T., Obara T., Murakami Y., Kuma K., Takamatsu J., Ohsawa N., Nagataki S. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. J Clin Endocrinol Metab. 80:1995;2607.
35. Derwahl M., Manole D., Sobke A., Broecker M. Pathogenesis of toxic thyroid adenomas and nodules. relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms Exp Clin Endocrinol Diabetes. 106:1998;S6.
36. Laglia G., Zeiger M.A., Leipricht A., Caturegli P., Levine M.A., Kohn L.D., Saji M. Increased cyclic adenosine 3′,5′-monophosphate inhibits G protein-coupled activation of phospholipase C in rat FRTL-5 thyroid cells. Endocrinology. 137:1996;3170.
37. Laurent E., Mockel J., Van Sande J., Graff I., Dumont J.E. Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. Mol Cell Endocrinol. 52:1987;273.
38. Van Sande J., Raspe E., Perret J., Lejeune C., Maenhaut C., Vassart G., Dumont J.E. Thyrotropin activates both the cyclic AMP and the PIP2 cascades in CHO cells expressing the human cDNA of TSH receptor. Mol Cell Endocrinol. 74:1990;R1.
39. Kosugi S., Shenker A., Mori T. Constitutive activation of cyclic AMP but not phosphatidylinositol signaling caused by four mutations in the 6th transmembrane helix of the human thyrotropin receptor. FEBS Lett. 356:1994;291.
40. Gorelov V.N., Dumon K., Barteneva N.S., Palm D., Röher H.-D., Goretzki P.E. Overexpression of Gsα subunit in thyroid tumors bearing a mutated Gsa gene. J Cancer Res Clin Oncol. 121:1995;219.
41. Saunier B., Dib K., Delemer B., Jacquemin C., Correze C. Cyclic AMP regulation of Gs protein. Thyrotropin and forskolin increase the quantity of stimulatory guanine nucleotide-binding proteins in cultured follicles. J Biol Chem. 265:1990;19942.
42. Muca C., Vallar L. Expression of mutationally activated Gαs stimulates growth and differentiation of thyroid FRTL5 cells. Oncogene. 9:1994;3647.
43. Nemoz G., Sette C., Hess M., Muca C., Vallar L., Conti M. Activation of cyclic nucleotide phosphodiesterases in FRTL-5 thyroid cells expressing a constitutively active Gsα Mol Endocrinol. 9:1995;1279.
44. Zeiger M.A., Saji M., Caturegli P., Westra W.H., Kohn L.D., Levine M.A. Transformation of rat thyroid follicular cells stably transfected with cholera toxin A1 fragment. Endocrinology. 137:1996;5392.
45. Ivan M., Ludgate M., Gire V., Bond J.A., Wynford-Thomas D. An amphotropic retroviral vector expressing a mutant gsp oncogene. effects on human thyroid cells in vitro J Clin Endocrinol Metab. 82:1997;2702.
46. Derwahl M., Hamacher C., Russo D., Broecker M., Manole D., Sehatz H., Kopp P., Filetti S. Constitutive activation of the Gsα protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. J Clin Endocrinol Metab. 81:1996;1898.
47. Michiels F.-M., Caillou B., Talbot M., Dessarps-Freichey F., Maunoury M.-T., Schlumberger M., Mercken L., Monier R., Freunteun J. Oncogenic potential of guanine nucleotide stimulatory factor α subunit in thyroid glands of transgenic mice. Proc Natl Acad Sci USA. 91:1994;10488.
48. Ledent C., Dumont J.E., Vassart G., Parmentier M. Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J. 11:1992;537.
49. Zeiger M.A., Saji M., Gusev Y., Westra W.H., Takiyama Y., Dooley W.C., Kohn L.D., Levine M.A. Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology. 138:1997;3133.
50. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Develop. 4:1994;82.
51. Wu J., Dent P., Jelinek T., Wolfman A., Weber M.J., Sturgill T.W. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science. 262:1993;1065.
52. Faure M., Bourne H.R. Differential effects of cAMP on the MAP kinase cascade. evidence for a cAMP-insensitive step that can bypass Raf-1 Mol Biol Cell. 6:1995;1025.
53. Saunier B., Tournier C., Jacquemin C., Pierre M. Stimulation of mitogen-activated protein kinase by thyrotropin in primary cultured human thyroid follicles. J Biol Chem. 270:1995;3693.